MedTrace Logo

CHESS: Human and Computer Mentors for Prostate Cancer Patients

NCT00516256 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2018-10-24

No results posted yet for this study

Summary

The aims include:

1. To measure the effect of the three study conditions on Quality of Life (QOL).

* CHESS and Cancer Information Mentor will not differ initially (6 weeks) or late in treatment (6 months) in QOL
* CHESS +Cancer Information Mentor will have the largest impact on QOL (initially and late in treatment) and will be significantly better than either CHESS or Cancer Information Mentor alone.
2. To measure potential intervening or mediating processes, so that we can determine how CHESS and the Cancer Information Mentor produce associated QOL benefits.
3. To conduct exploratory use analyses examining which types of CHESS content, sequential patterns of content use, or other characteristics of use behavior are associated with greater pretest-posttest improvements in QOL.
4. To conduct a secondary analysis exploring whether men whose partners have actively used CHESS do better than those whose partners did not use CHESS.

Conditions

Interventions

BEHAVIORAL

CHESS System

Internet-based computer program for 6 months.

BEHAVIORAL

Cancer Information Mentor

Phone calls to the patient for 6 months.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Cindy Carmack Taylor, PhD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-03
Primary Completion
2018-05-11
Completion
2018-05-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00516256 on ClinicalTrials.gov